provides Immutep and its potential partners flexibility for late-stage clinical provides Immutep and its potential partners flexibility for late-stage clinical An amazing announcement though. There certainly aren’t any other Australian cancer focused biotechs that are in phase 3 (even if IMM doesn’t proceed with MBC/TNBC it’s still an amazing achievement). And to have it as a phase 2/3 no less - which expedites the whole trial.
but here we are - an amazing 1.75% increase in the share price. Other companies it would’ve meant a 100% re-rate.
a positive in the announcement at least is the reference that it provides “potential partners flexibility of late stage clinical development”.
have a great Christmas everyone and here’s hoping for a better 2023 for long suffering shareholders
Ann: Update on MBC trial design following successful FDA meeting, page-7
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |